Nektar Therapeutics NKTR Debt-to-equity

Debt-to-equity at other companies

AmgenAMGN

4.9×-2.7×

Regeneron PharmaceuticalsREGN

0.1×0.0×

Artiva Biotherapeutics, Inc.ARTV

0×-0.1×

Vera TherapeuticsVERA

0.2×0.0×

Viridian Therapeutics, Inc.VRDN

0.2×+0.1×

Vor BiopharmaVOR

0.5×+0.2×

FAQ

What is Nektar Therapeutics's debt-to-equity?

Nektar Therapeutics (NKTR) reported debt-to-equity of 0.1× in Q1 2026.

How has Nektar Therapeutics's debt-to-equity changed year-over-year?

Nektar Therapeutics's debt-to-equity decreased by 98.0% year-over-year, from 7.3× to 0.1×.

What is the long-term trend for Nektar Therapeutics's debt-to-equity?

Over 5 years (2020 to 2025), Nektar Therapeutics's debt-to-equity has grown at a 46.9% compound annual growth rate (CAGR), from 0.1× to 1×.

What does debt-to-equity mean?

Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.